BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9806323)

  • 1. Actions of novel antidiabetic thiazolidinedione, T-174, in animal models of non-insulin-dependent diabetes mellitus (NIDDM) and in cultured muscle cells.
    Arakawa K; Ishihara T; Aoto M; Inamasu M; Saito A; Ikezawa K
    Br J Pharmacol; 1998 Oct; 125(3):429-36. PubMed ID: 9806323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats.
    Fujiwara T; Yoshioka S; Yoshioka T; Ushiyama I; Horikoshi H
    Diabetes; 1988 Nov; 37(11):1549-58. PubMed ID: 3053303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals.
    Ikeda H; Taketomi S; Sugiyama Y; Shimura Y; Sohda T; Meguro K; Fujita T
    Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):156-62. PubMed ID: 2334455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Actions of the novel oral antidiabetic agent HQL-975 in insulin-resistant non-insulin-dependent diabetes mellitus model animals.
    Ishikawa Y; Saito MN; Ikemoto T; Takeno H; Watanabe K; Tani T
    Diabetes Res Clin Pract; 1998 Aug; 41(2):101-11. PubMed ID: 9789716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidiabetic activity of perylenequinonoid-rich extract from Shiraia bambusicola in KK-Ay mice with spontaneous type 2 diabetes mellitus.
    Huang M; Zhao P; Xiong M; Zhou Q; Zheng S; Ma X; Xu C; Yang J; Yang X; Zhang TC
    J Ethnopharmacol; 2016 Sep; 191():71-81. PubMed ID: 27286915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555.
    Upton R; Widdowson PS; Ishii S; Tanaka H; Williams G
    Br J Pharmacol; 1998 Dec; 125(8):1708-14. PubMed ID: 9886762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative.
    Shibata T; Matsui K; Nagao K; Shinkai H; Yonemori F; Wakitani K
    Eur J Pharmacol; 1999 Jan; 364(2-3):211-9. PubMed ID: 9932726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pioglitazone-induced increase of insulin sensitivity in the muscles of the obese Zucker fa/fa rat cannot be explained by local adipocyte differentiation.
    Hallakou S; Foufelle F; Doaré L; Kergoat M; Ferré P
    Diabetologia; 1998 Aug; 41(8):963-8. PubMed ID: 9726600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidiabetic effects of flavonoids from Sophora flavescens EtOAc extract in type 2 diabetic KK-ay mice.
    Yang X; Yang J; Xu C; Huang M; Zhou Q; Lv J; Ma X; Ke C; Ye Y; Shu G; Zhao P
    J Ethnopharmacol; 2015 Aug; 171():161-70. PubMed ID: 26051831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats.
    Minoura H; Takeshita S; Kimura C; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Mutoh S
    Diabetes Obes Metab; 2007 May; 9(3):369-78. PubMed ID: 17391165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The development of overt diabetes in young Zucker Diabetic Fatty (ZDF) rats and the effects of chronic MCC-555 treatment.
    Pickavance L; Widdowson PS; King P; Ishii S; Tanaka H; Williams G
    Br J Pharmacol; 1998 Oct; 125(4):767-70. PubMed ID: 9831913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent.
    Fujita T; Sugiyama Y; Taketomi S; Sohda T; Kawamatsu Y; Iwatsuka H; Suzuoki Z
    Diabetes; 1983 Sep; 32(9):804-10. PubMed ID: 6354788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice.
    Shiuchi T; Iwai M; Li HS; Wu L; Min LJ; Li JM; Okumura M; Cui TX; Horiuchi M
    Hypertension; 2004 May; 43(5):1003-10. PubMed ID: 15037562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats.
    Kramer D; Shapiro R; Adler A; Bush E; Rondinone CM
    Metabolism; 2001 Nov; 50(11):1294-300. PubMed ID: 11699047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pioglitazone treatment for 7 days failed to correct the defect in glucose transport and glucose transporter translocation in obese Zucker rat (fa/fa) skeletal muscle plasma membranes.
    Hirshman MF; Fagnant PM; Horton ED; King PA; Horton ES
    Biochem Biophys Res Commun; 1995 Mar; 208(2):835-45. PubMed ID: 7695642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats.
    Sugiyama Y; Taketomi S; Shimura Y; Ikeda H; Fujita T
    Arzneimittelforschung; 1990 Mar; 40(3):263-7. PubMed ID: 2189419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action.
    Zierath JR; Ryder JW; Doebber T; Woods J; Wu M; Ventre J; Li Z; McCrary C; Berger J; Zhang B; Moller DE
    Endocrinology; 1998 Dec; 139(12):5034-41. PubMed ID: 9832442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-diabetic effects of globin digest and its active ingredient Leu-Ser-Glu-Leu in ICR mice, streptozotocin-induced diabetic mice and KK-Ay mice.
    Nakaoka F; Sasakawa Y; Yamamoto K; Nakao M; Nakamura M; Tong C; Fukuhama C; Kagawa K
    Life Sci; 2010 Mar; 86(11-12):424-34. PubMed ID: 20109472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan.
    Yamasaki Y; Kawamori R; Wasada T; Sato A; Omori Y; Eguchi H; Tominaga M; Sasaki H; Ikeda M; Kubota M; Ishida Y; Hozumi T; Baba S; Uehara M; Shichiri M; Kaneko T
    Tohoku J Exp Med; 1997 Nov; 183(3):173-83. PubMed ID: 9550126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of interleukin 17 in angiotensin II type 1 receptor-mediated insulin resistance.
    Ohshima K; Mogi M; Jing F; Iwanami J; Tsukuda K; Min LJ; Higaki J; Horiuchi M
    Hypertension; 2012 Feb; 59(2):493-9. PubMed ID: 22184328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.